Specifically, in Western countries, 45% of NSCLC tumors harbor mutations in KRAS proto‐oncogene, GTPase (KRAS), epidermal growth factor receptor (EGFR) or B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) genes; while driver gene fusions and splicing variants are present in 10–15% of patients. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.